Navigation Links
CVS Caremark Reports First Quarter Results
Date:5/5/2011

WOONSOCKET, R.I., May 5, 2011 /PRNewswire/ -- CVS Caremark Corporation (NYSE: CVS), today announced revenues, operating profit, and net income for the three months ended March 31, 2011.

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO)

First Quarter Year-Over-Year Highlights:

  • Net revenues increased 8.9% to a record $25.9 billion
  • Pharmacy Services segment revenues increased 18.4%
  • Retail Pharmacy segment revenues increased 4.4%, with same stores sales up 2.6%
  • Adjusted diluted EPS from continuing operations of $0.57
  • GAAP diluted EPS from continuing operations of $0.52

  • Guidance:

  • Full-year Adjusted diluted EPS from continuing operations reaffirmed at $2.72 - $2.82
  • Full-year GAAP diluted EPS from continuing operations reaffirmed at $2.52 – $2.62

  • Revenues:Net revenues for the three months ended March 31, 2011 increased $2.1 billion to a record $25.9 billion, up from $23.8 billion during the three months ended March 31, 2010.

    Revenues in the Pharmacy Services segment increased 18.4% to $14.0 billion in the three months ended March 31, 2011. This increase was primarily associated with the addition of the previously announced long-term contract with Aetna. Retail network claims processed during the three months ended March 31, 2011 increased 19.5% to 157.7 million, compared to 132.0 million in the prior year period. The increase in retail network claims was primarily due to the Aetna contract as well as an increase in Medicare Part D prescription drug claims as a result of increases in covered lives. Mail choice claims processed during the three months ended March 31, 2011 increased approximately 13.0% to 17.5 million compared to 15.5 million in the prior year period. The increase in the mail choice claim volume was also driven by the Aetna contract.

    Revenues in the Retail Pharmacy segment increased 4.4% to $14.6 billion in the three months ended March 31, 2011. Same store sales increased 2.6% over the prior year period. Pharmacy same store sales rose 3.7%, reflecting a strong flu season as well as a positive impact from Maintenance Choice™ of approximately 170 basis points on a net basis (i.e., a positive impact of approximately 220 basis points on a gross basis, net of approximately 50 basis points from the conversion of 30-day prescriptions at retail to 90-day prescriptions under the Maintenance Choice program).  Pharmacy same store sales were negatively impacted by approximately 260 basis points due to recent generic introductions. Front store same store sales increased 0.4% in the three months ended March 31, 2011. As expected front store sales were negatively impacted by approximately 45 basis points due to the shift of sales related to the Easter holiday into the second quarter, and by approximately 65 basis points due to the absence of sales associated with the grand reopening of the Longs stores in the prior year.

    Income from continuing operations attributable to CVS Caremark:Income from continuing operations attributable to CVS Caremark for the three months ended March 31, 2011, decreased $59 million to $714 million, compared with $773 million during the three months ended March 31, 2010. The decline in our income from continuing operations was driven by lower gross profit in our Pharmacy Services segment primarily as a result of pricing compression relating to contract renewals, and in particular the renewal of a large government contract that took effect during the third quarter of 2010.  Additionally, as expected, our effective income tax rate improved during the quarter to 39.4% compared to 39.8% in the prior year period, primarily due to changes in the effective state tax rates.  Adjusted earnings per share from continuing operations attributable to CVS Caremark, which excludes $106 million of intangible asset amortization related to acquisition activity, for the three months ended March 31, 2011 were $0.57, compared with $0.60 in the three months ended March 31, 2010. GAAP earnings per diluted share from continuing operations attributable to CVS Caremark for the three months ended March 31, 2011 were $0.52, compared with $0.55 in the three months ended March 31, 2010.

    Larry Merlo, President and Chief Executive Officer, stated: "2011 is off to a good start, with results slightly above guidance for both our retail and PBM businesses.   We also generated $1.6 billion in free cash this quarter, more than double the amount we generated in last year's first quarter. Our retail business continues to grow and gain share, and our new store clustering initiatives are yielding promising results."

    Mr. Merlo continued, "The PBM's 2012 selling season is also off to a good start, and adoption of our integrated offerings is growing. The Aetna implementation and PBM streamlining initiatives are both proceeding well and on schedule. I remain confident in our ability to execute our operating plans and improve the performance of our PBM for 2012 and beyond."

    Acquisition of Universal American Medicare Part D Business:On April 29, 2011, the Company acquired the Medicare prescription drug business of Universal American Corp. (the "UAM Medicare Part D Business"). As previously announced, the Company paid cash consideration of $1.25 billion plus $185 million (the amount of excess capital that resided in the entities that operate the UAM Medicare Part D Business), less $110 million (the amount of Universal American Corp.'s outstanding trust preferred securities which are being assumed by the Company).  The UAM Medicare Part D Business offers prescription drug plan benefits to Medicare beneficiaries throughout the United States through its Community CCRx(SM) prescription drug plan.  With the inclusion of this acquisition the Company now provides Medicare Part D benefits to over 3 million beneficiaries. The Company continues to expect the acquisition of the UAM Medicare Part D Business to be approximately $0.08 accretive to adjusted diluted earnings per share for the remainder of the year.

    Real estate program:During the three months ended March 31, 2011, the Company opened 57 new retail drugstores, one new retail specialty pharmacy store and closed 13 retail drugstores. In addition, the Company relocated 49 retail drugstores. As of March 31, 2011, the Company operated 7,314 locations, included in which were 7,226 retail drugstores, 66 specialty pharmacy stores, 18 specialty mail order pharmacies and four mail order pharmacies in 44 states, the District of Columbia and Puerto Rico.

    Guidance:In light of the solid performance reported today and continued confidence about the remainder of the year, the Company is reaffirming its earnings per share guidance ranges for the full year 2011.  As previously announced, the Company expects adjusted earnings per share from continuing operations to be in the range of $2.72 - $2.82 and GAAP earnings per share from continuing operations to be in the range of $2.52 – $2.62.

    Teleconference and webcast:The Company will be holding a conference call today for the investment community at 8:30 am (EDT) to discuss its quarterly results. An audio webcast of the conference call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Caremark website at http://info.cvscaremark.com. This webcast will be archived and available on the website for a one-month period following the conference call.

    About the Company:CVS Caremark is the largest pharmacy health care provider in the United States. Through our integrated offerings across the entire spectrum of pharmacy care, we are uniquely positioned to provide greater access to engage plan members in behaviors that improve their health, and to lower overall health care costs for health plans, plan sponsors and their members. CVS Caremark is a market leader in mail order pharmacy, retail pharmacy, specialty pharmacy, and retail clinics, and is a leading provider of Medicare Part D Prescription Drug Plans. As one of the country's largest pharmacy benefits managers (PBMs), we provide access to a network of more than 65,000 pharmacies, including over 7,200 CVS/pharmacy® stores that provide unparalleled service and capabilities. Our clinical expertise includes one of the industry's most comprehensive disease management programs. General information about CVS Caremark is available through the Company's website at http://info.cvscaremark.com.

    Forward-looking statements:This press release contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2010.

    – Tables Follow –CVS CAREMARK CORPORATIONCondensed Consolidated Statements of Income(Unaudited)Three Months Ended March 31,In millions, except per share amounts

    20112010Net revenues

    $
    25,880$
    23,760Cost of revenues

    21,12919,014Gross profit

    4,7514,746Operating expenses

    3,4403,336Operating profit

    1,3111,410Interest expense, net

    134128Income before income tax provision

    1,1771,282Income tax provision

    464510Income from continuing operations

    713772Loss from discontinued operations, net of tax

    (1)(2)Net income

    712770Net loss attributable to noncontrolling interest

    11Net income attributable to CVS Caremark

    $
    713$
    771Income from continuing operations attributable to CVS Caremark:Income from continuing operations

    $
    713$
    772Net loss attributable to noncontrolling interest

    11Income from continuing operations attributable to CVS Caremark

    $
    714$
    773Basic earnings per common share:

     Income from continuing operations attributable to CVS Caremark   $
    .52   $
    .56 Loss from discontinued operations attributable to CVS Caremark

    —— Net income attributable to CVS Caremark

    $
    .52$
    .56 Weighted average basic common shares outstanding

    1,3621,386Diluted earnings per common share:

     Income from continuing operations attributable to CVS Caremark$
    .52$
    .55 Loss from discontinued operations attributable to CVS Caremark

    —— Net income attributable to CVS Caremark

    $
    .52$
    .55 Weighted average diluted common shares outstanding

    1,3711,396Dividends declared per common share

    $   0.1250$  0.0875CVS CAREMARK CORPORATIONCondensed Consolidated Balance Sheets(Unaudited)In millions, except per share amounts

    March 31,

    2011December 31,

    2010Assets: Cash and cash equivalents

    $  2,162$  1,427Short-term investments

    64 Accounts receivable, net

    5,3484,925 Inventories

    10,18110,695 Deferred income taxes

    509511 Other current assets

    174144Total current assets

    18,38017,706 Property and equipment, net

    8,3508,322 Goodwill

    25,66625,669 Intangible assets, net

    9,6929,784 Other assets

    740688Total assets

    $  62,828$  62,169Liabilities: Accounts payable

    $  4,354$  4,026 Claims and discounts payable

    2,7762,569 Accrued expenses

    3,2293,070 Short-term debt

    300300 Current portion of long-term debt

    8061,105Total current liabilities

    11,46511,070 Long-term debt

    8,6698,652 Deferred income taxes

    3,7103,655 Other long-term liabilities

    1,0321,058 Commitments and contingencies  Redeemable noncontrolling interest

    3334Shareholders' equity:Preferred stock, par value $0.01: 0.1 shares authorized; none issued or
    outstanding

    ——Common stock, par value $0.01: 3,200 shares authorized; 1,627 shares
    issued and 1,354 shares outstanding at March 31, 2011 and 1,624
    shares issued and 1,363 shares outstanding at December 31, 2010Treasury stock, at cost: 271 shares at March 31, 2011 and 259 shares
    at December 31, 2010(9,449)(9,030)Shares held in trust: 2 shares at March 31, 2011 and December 31,
    2010

    (56)(56)Capital surplus

    27,70627,610Retained earnings

    19,84519,303Accumulated other comprehensive loss

    (143)(143)Total shareholders' equity

    37,91937,700Total liabilities and shareholders' equity

    $  62,828$  62,169CVS CAREMARK CORPORATIONCondensed Consolidated Statements of Cash Flows(Unaudited) Three Months Ended March 31,In millions

    20112010Cash flows from operating activities: Cash receipts from revenues

    $  22,971$  22,918 Cash paid for inventory and prescriptions dispensed by retail network pharmacies

    (17,445)(17,581) Cash paid to other suppliers and employees

    (3,342)(3,916) Interest received

    11 Interest paid

    (150)(155) Income taxes paid

    (169)(207)Net cash provided by operating activities

    1,8661,060Cash flows from investing activities: Purchases of property and equipment

    (309)(401) Proceeds from sale-leaseback transactions

    11— Proceeds from sale of property and equipment

    1212 Acquisitions (net of cash acquired) and other investments

    (11)(9) Purchase of short-term investments

    (2)— Maturity of short-term investments

    —1Net cash used in investing activities

    (299)(397)Cash flows from financing activities: Increase (decrease) in short-term debt

    —200 Repayments of long-term debt

    (301)(1) Dividends paid

    (171)(122) Proceeds from exercise of stock options

    10797 Excess tax benefits from stock-based compensation

    —11Repurchase of common stock

    (467)(887)Net cash used in financing activities

    (832)(702)Net increase (decrease) in cash and cash equivalents

    735(39)Cash and cash equivalents at beginning of period

    1,4271,086Cash and cash equivalents at end of period

    $  2,162$  1,047Reconciliation of net income to net cash provided by operating activities: Net income

    $  712$  770 Adjustments required to reconcile net income to net cashprovided by operating activities:Depreciation and amortization

    374358Stock-based compensation

    3637Deferred income taxes and other non-cash items

    702Change in operating assets and liabilities, net of effects of acquisitions:Accounts receivable, net

    (423)308Inventories

    51468Other current assets

    (30)(39)Other assets

    (52)—Accounts payable and claims and discounts payable

    535(115)Accrued expenses

    156(335)Other long-term liabilities

    (26)6Net cash provided by operating activities

    $  1,866$  1,060Adjusted Earnings Per Share(Unaudited)For internal comparisons, management finds it useful to assess year-to-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.The Company defines adjusted earnings per share as income before income tax provision plus amortization, less adjusted income tax provision, plus net loss attributable to noncontrolling interest divided by the weighted average diluted common shares outstanding.The following is a reconciliation of income before income tax provision to adjusted earnings per share:Three Months Ended March 31,In millions, except per share amounts

    20112010Income before income tax provision

    $
    ,177$
    ,282Amortization5Adjusted income before income tax provision

    1,2831,387Adjusted income tax provision(1)

    506552Adjusted income from continuing operations777835Net loss attributable to noncontrolling interest

    11Adjusted income from continuing operations attributable to CVS Caremark

    $
    778$
    836Weighted average diluted common shares outstanding

    1,3711,396Adjusted earnings per share from continuing operations attributable to CVS Caremark

    $
    .57$
    .60(1) The adjusted income tax provision is computed using the effective income tax rate from the condensed consolidated statement of income.Free Cash Flow(Unaudited)The Company defines free cash flow as net cash provided by operating activities less net additions to properties and equipment (i.e., additions to property and equipment plus proceeds from sale-leaseback transactions).The following is a reconciliation of net cash provided by operating activities to free cash flow:Three Months EndedMarch 31, In millions

    20112010Net cash provided by operating activities

    $  1,866$  1,060 Subtract:  Additions to property and equipment

    (309)(401) Add:  Proceeds from sale-leaseback transactions

    11—Free cash flow

    $  1,568$
    59Supplemental Information(Unaudited)The Company evaluates its Pharmacy Services and Retail Pharmacy segment performance based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. The Company evaluates the performance of its Corporate segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The following is a reconciliation of the Company's segments to the accompanying consolidated financial statements:In millions

    Pharmacy Services

    Segment(1) Retail Pharmacy SegmentCorporate  SegmentIntersegment Eliminations(2) Consolidated

    TotalsThree Months Ended: March 31, 2011:Net revenues

    $  14,014$
    4,587$  —$
    (2,721)$
    25,880Gross profit

    6394,147—(35)4,751Operating profit (loss)

    3971,096(147)(35)1,311March 31, 2010:Net revenues

    $  11,836$  13,978$  —$  (2,054)$  23,760Gross profit

    7823,987—(23)4,746Operating profit (loss)

    5381,030(135)(23)1,410(1) Net revenues of the Pharmacy Services segment include approximately $2.2 billion and $1.7 billion of retail co-payments for the three months ended March 31, 2011 and 2010, respectively.

    (2) Intersegment eliminations relate to two types of transactions: (i) Intersegment revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue on a standalone basis, and (ii) Intersegment revenues, gross profit and operating profit that occur when Pharmacy Services segment customers, through the Company's intersegment activities (such as the Maintenance Choice™ program), elect to pick-up their maintenance prescriptions at Retail Pharmacy segment stores instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue, gross profit and operating profit on a standalone basis.  As a result, both the Pharmacy Services and the Retail Pharmacy segments include the following results associated with this activity: net revenues of $558 million and $340 million for the three months ended March 31, 2011 and 2010, respectively, gross profit and operating profit of $35 million and $23 million for the three months ended March 31, 2011 and 2010, respectively. Supplemental Information(Unaudited)Pharmacy Services SegmentThe following table summarizes the Pharmacy Services segment's performance for the respective periods:Three Months EndedMarch 31, In millions

    20112010Net revenues

    $   14,014$   11,836Gross profit

    639782Gross profit % of net revenues

    4.6%6.6%Operating expenses

    242244Operating expense % of net revenues

    1.7%2.1%Operating profit

    397538Operating profit % of net revenues

    2.8%4.5%Net revenues(1):  Mail choice(2)

    $4,535$4,078 Pharmacy network(3)

    9,3777,670 Other

    10288Pharmacy claims processed(1): Total

    175.2147.5 Mail choice(2)

    17.515.5 Pharmacy network(3)

    157.7132.0Generic dispensing rate(1): Total

    73.8%70.4% Mail choice(2)

    63.8%58.8% Pharmacy network(3)

    74.8%71.6%Mail choice penetration rate

    24.1%24.8%(1) Pharmacy network net revenues, claims processed and generic dispensing rates do not include Maintenance Choice, which are included within the mail choice category.

    (2) Mail choice is defined as claims filled at a Pharmacy Services' mail facility, which includes specialty mail claims, as well as 90-day claims filled at retail under the Maintenance Choice program.

    (3) Pharmacy network is defined as claims filled at retail pharmacies, including our retail drugstores.EBITDA and EBITDA per Adjusted Claim(Unaudited)The Company defines EBITDA as earnings before interest, taxes, depreciation and amortization. We define EBITDA per adjusted claim as EBITDA divided by adjusted pharmacy claims. Adjusted pharmacy claims normalize the claims volume statistic for the difference in average days' supply for mail and retail claims. Adjusted pharmacy claims are calculated by multiplying 90-day claims (the majority of total mail claims) by 3 and adding the 30-day claims. EBITDA can be reconciled to operating profit, which we believe to be the most directly comparable GAAP financial measure.The following is a reconciliation of operating profit to EBITDA for the Pharmacy Services segment:Three Months Ended March 31,In millions, except per adjusted claim amounts

    20112010Operating profit

    $
    397$  538Depreciation and amortization

    9998EBITDA

    496636 Adjusted claims

    207.6175.5EBITDA per adjusted claim

    $   2.39$  3.62.

    Supplemental Information(Unaudited)Retail Pharmacy SegmentThe following table summarizes the Retail Pharmacy segment's performance for the respective periods:Three Months Ended March 31, In millions

    20112010Net revenues

    $14,587$13,978Gross profit

    4,1473,987Gross profit % of net revenues

    28.4%28.5%Operating expenses

    3,0512,957Operating expense % of net revenues

    20.9%21.2%Operating profit

    1,0961,030Operating profit % of net revenues

    7.5%7.4%Net revenue increase: Total

    4.4%3.6% Pharmacy

    5.1%4.6% Front store

    2.8%1.3%Same store sales increase (decrease):  Total

    2.6%2.3% Pharmacy

    3.7%3.7% Front store

    0.4%(0.7)%Generic dispensing rate

    75.2%72.1%Pharmacy % of total revenues

    69.1%68.4%Third party % of pharmacy revenue

    97.5%97.0%Retail prescriptions filled

    165.6157.3Adjusted Earnings Per Share Guidance(Unaudited)The following reconciliation of estimated income before income tax provision to estimated adjusted earnings per share contains forward-looking information that is subject to risks and uncertainties that could cause actual results to differ materially. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2010. For internal comparisons, management finds it useful to assess year-to-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.Year EndingIn millions, except per share amounts

    December 31, 2011Income before income tax provision

    $  5,606$  5,816Amortization

    460460Adjusted income before income tax provision

    6,0666,276Adjusted income tax provision

    2,3842,466Adjusted income from continuing operations

    3,6823,810Net loss attributable to noncontrolling interest

    44Adjusted income from continuing operations attributable to CVS Caremark

    $  3,686$  3,814Weighted average diluted common shares outstanding

    1,3541,354Adjusted earnings per share from continuing operations attributable to CVS Caremark

    $  2.72$  2.82Free Cash Flow Guidance(Unaudited)The following reconciliation of net cash provided by operating activities to free cash flow contains forward-looking information that is subject to risks and uncertainties that could cause actual results to differ materially. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2010. For internal comparisons, management finds it useful to assess year-to-year cash flow performance by adjusting cash provided by operating activities, by capital expenditures and proceeds from sale-leaseback transactions.Year EndingIn millions

    December 31, 2011 Net cash provided by operating activities

    $  5,454$  5,654 Subtract:  Additions to property and equipment

    (2,100)(2,050) Add:  Proceeds from sale-leaseback transactions

    600550Free cash flow

    $  3,954$  4,154
    '/>"/>

    SOURCE CVS Caremark Corporation
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year
    2. CVS Caremark Data Confirms Improved Outcomes for Women with Osteoporosis Who are Adherent to Therapy
    3. CVS Caremark Launches Distribution of $3 million in Free Seasonal Flu Shot Vouchers to the Unemployed
    4. CVS Caremark Celebrates Outstanding Pharmacy Care to Patients During American Pharmacists Month in October
    5. CVS Caremark Undertakes Multi-Year Study to Improve Patient Medication Adherence
    6. CVS Caremark Announces Updates to Flu Vaccine Program
    7. CVS Caremarks MinuteClinic and Allina Hospitals & Clinics Form Strategic Partnership
    8. CVS Caremark Corporation Increases Quarterly Dividend 15%
    9. CVS Caremarks MinuteClinic Becomes First Retail Clinic Provider to Achieve Consecutive Accreditation Awards From The Joint Commission
    10. CVS Caremark Names New Chief Human Resources Officer
    11. CVS Caremark Corporation Announces Quarterly Dividend
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
    (Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
    (Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
    (Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
    (Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
    (Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
    (Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
    Breaking Medicine News(10 mins):